133,665 Shares in Zepp Health Corporation Sponsored ADR $ZEPP Bought by Monolith Management Ltd

Monolith Management Ltd bought a new position in shares of Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 133,665 shares of the company’s stock, valued at approximately $3,601,000. Zepp Health comprises approximately 1.3% of Monolith Management Ltd’s investment portfolio, making the stock its 15th biggest position. Monolith Management Ltd owned approximately 0.92% of Zepp Health as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Trivest Advisors Ltd acquired a new position in Zepp Health during the third quarter worth $13,503,000. Millennium Management LLC acquired a new position in Zepp Health during the third quarter worth $11,265,000. UBS Group AG boosted its holdings in Zepp Health by 16,412.0% during the third quarter. UBS Group AG now owns 181,302 shares of the company’s stock worth $8,300,000 after purchasing an additional 180,204 shares during the last quarter. State Street Corp acquired a new position in Zepp Health during the fourth quarter worth $3,421,000. Finally, Keystone Investors PTE Ltd. acquired a new position in Zepp Health during the third quarter worth $4,811,000. Institutional investors and hedge funds own 52.61% of the company’s stock.

Zepp Health Stock Performance

NYSE ZEPP opened at $5.14 on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average price is $11.10 and its two-hundred day moving average price is $18.46. Zepp Health Corporation Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $61.85. The firm has a market capitalization of $75.46 million, a P/E ratio of -2.04 and a beta of 1.78.

Wall Street Analysts Forecast Growth

Separately, Fundamental Research set a $56.28 price target on shares of Zepp Health and gave the stock a “buy” rating in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.28.

Zepp Health Profile

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.